For sequential administration regimens, the tumour-bearing mice were either treated with olaparib, AZD1775 and anti-PD-1 or olaparib, AZD1775 and ADU-S100 on day 1, followed by ADU-S100 or anti-PD-1 on day 22, respectively. This evidence concerns the gene PDCD1 and neoplasm.